Profiel
Jennifer Viera is currently the Head-Investor Relations & Communications at Enanta Pharmaceuticals, Inc. She previously worked as the Senior Director-Corporate Communications at OvaScience, Inc. and as the Investor & Media Contact at Tetraphase Pharmaceuticals, Inc.
Actieve functies van Jennifer Viera
| Bedrijven | Functie | Begin |
|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Investor Relations Contact | 01-01-2023 |
Eerdere bekende functies van Jennifer Viera
| Bedrijven | Functie | Einde |
|---|---|---|
OvaScience, Inc.
 OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Corporate Officer/Principal | - |
| TETRAPHASE PHARMACEUTICALS, INC. | Investor Relations Contact | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Health Technology |
